Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.

× No keyword cloud information.

10 in total

1. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder.

Authors: M Khorsand; J Lange; L Feun; N J Clendeninn; M Collier; G Wilding
Journal: Invest New Drugs Date: 1997 Impact factor: 3.850

2. Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas.

Authors: Nozomu Tanji; Akira Ozawa; Noriyoshi Miura; Yutaka Yanagihara; Toyokazu Sasaki; Takayasu Nishida; Tadahiko Kikugawa; Tetsuhiro Ikeda; Tatsumasa Ochi; Kenji Shimamoto; Katsunori Aoki; Masayoshi Yokoyama
Journal: Int J Clin Oncol Date: 2010-03-26 Impact factor: 3.402

Review 3. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors.

Authors: C Bokemeyer; J T Hartmann; M A Kuczyk; M C Truss; J Beyer; U Jonas; L Kanz
Journal: World J Urol Date: 1996 Impact factor: 4.226

4. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.

Authors: Ji Eun Uhm; Ho Yeong Lim; Won Seog Kim; Han Yong Choi; Hyun Moo Lee; Byeong-Bae Park; Keunchil Park; Won Ki Kang
Journal: Neoplasia Date: 2007-01 Impact factor: 5.715

5. Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?

Authors: Kensuke Bekku; Takashi Saika; Yasuyuki Kobayashi; Ryo Kioshimoto; Taiki Kanbara; Yasutomo Nasu; Hiromi Kumon
Journal: Int J Clin Oncol Date: 2011-11-18 Impact factor: 3.402

6. Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.

Authors: Yu Ri Seo; Se Hyung Kim; Hyun Jung Kim; Chan Kyu Kim; Seong Kyu Park; Eun Suk Koh; Dae Sik Hong
Journal: J Hematol Oncol Date: 2010-01-20 Impact factor: 17.388

7. Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group.

Authors: Bruce J Roth; Judith Manola; Robert Dreicer; David Graham; George Wilding
Journal: Invest New Drugs Date: 2002-11 Impact factor: 3.850

8. Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience.

Authors: Akira Ozawa; Nozomu Tanji; Tatsumasa Ochi; Yutaka Yanagihara; Tadahiko Kikugawa; Akiko Yamaguchi; Tetsuhiro Ikeda; Kenji Shimamoto; Katsunori Aoki; Akihiko Toshino; Masayoshi Yokoyama
Journal: Int J Clin Oncol Date: 2007-08-20 Impact factor: 3.402

Review 9. A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.

Authors: Fu-Shun Hsu; Chun-Hung Su; Kou-How Huang
Journal: J Immunol Res Date: 2017-12-10 Impact factor: 4.818

10. Doxorubicin Embedded into Nanofibrillated Bacterial Cellulose (NFBC) Produces a Promising Therapeutic Outcome for Peritoneally Metastatic Gastric Cancer in Mice Models via Intraperitoneal Direct Injection.

Authors: Hidenori Ando; Takashi Mochizuki; Amr S Abu Lila; Shunsuke Akagi; Kenji Tajima; Kenji Fujita; Taro Shimizu; Yu Ishima; Tokuo Matsushima; Takatomo Kusano; Tatsuhiro Ishida
Journal: Nanomaterials (Basel) Date: 2021-06-28 Impact factor: 5.076

10 in total